July 2024 - Page 9 of 12

ISTH Academician’s Voices | Academician Heyu Ni: Leading Thrombosis Research and Uniting Global Chinese Scientists in Advancing International Research

By Mourabit Halima 2024.07.10

The 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) Congress was held in Bangkok, Thailand, from June 22 to June 26, 2024. As the most influential event in the field of thrombosis and hemostasis, the ISTH Congress attracts thousands of top experts and scholars from around the world with its profound academic impact and rich content. During this prestigious event, Oncology Frontier-Hematology Frontier had the honor of interviewing Academician Heyu Ni from the Canadian Academy of Health Sciences, who also served as the Chair of the Joint ISTH Congress and Global Chinese Thrombosis and Hemostasis Conference. In this interview, Academician Ni shared his extensive academic experience and unique insights, providing us with valuable academic reflections and perspectives. We have organized this interview into an article for our readers.

CDL (China Diabetes and Liver Disease Co-management Action Plan) Literature Monthly Review—June 2024, Issue 17

By Mourabit Halima 2024.07.10

Diabetes and liver disease are prevalent chronic conditions in China. They often interact in terms of pathogenesis, clinical manifestations, and treatment targets, acting as mutual risk factors. Joint management can alleviate the disease burden. To support the development of co-management of diabetes and liver disease in China, this journal, in collaboration with the CDL (China Diabetes and Liver Disease Co-management Action Plan), launches the CDL Literature Monthly Review column. Each month, we share relevant research on the mechanisms and treatment advancements of diabetes combined with liver disease, inviting experts in the field to provide commentary. This aims to offer insights and assistance to researchers and frontline medical professionals in scientific research and clinical practice.

Case Sharing: A Case of Hepatic Sinusoidal Obstruction Syndrome Induced by Combined Drug and Alcohol Use

By Mourabit Halima 2024.07.09

Hepatic sinusoidal obstruction syndrome (HSOS), also known as hepatic veno-occlusive disease, is a common secondary vascular liver disease caused by various factors leading to damage to sinusoidal endothelial cells, resulting in sinusoidal obstruction and hepatic congestion. Clinically, it primarily presents with abdominal distension, liver pain, rapid ascites accumulation, hepatomegaly, and jaundice, which can lead to severe liver dysfunction, multi-organ failure, and even death. Professor Qingchun Fu's team from the Shanghai Public Health Clinical Center shares a clinical case and their experience in diagnosing and treating a patient with HSOS induced by combined drug and alcohol use.

Advances in Clinical Research on Curing Chronic Hepatitis B in NAs-treated Populations by Professor Li Li

By Mourabit Halima 2024.07.09

Recently, the 25th National Conference on Traditional Chinese Medicine and Hepatobiliary Diseases organized by the Chinese Association of Traditional Chinese Medicine was successfully held in Chongqing. The conference invited distinguished TCM masters, academicians, renowned TCM experts, and hepatology specialists from across the country to deliver academic reports, focusing on the hot and challenging issues in the diagnosis and treatment of liver diseases with TCM. At the conference, Professor Li Li from Beijing Hospital of Traditional Chinese Medicine, presented a report titled "Latest Advances in the Clinical Cure of Chronic Hepatitis B." The following is a summary of the report for our readers.

Xinghai Forum: Professors Baoliang Guo and Guiying Xu Share Research Progress on ctDNA Monitoring in Breast Cancer

By Mourabit Halima 2024.07.09

Circulating tumor DNA (ctDNA) testing allows for continuous dynamic monitoring of tumor genetic variations without relying on tissue samples. This liquid biopsy technology has been widely used in clinical breast cancer research for prognosis and treatment evaluation, but there are still no standards for ctDNA testing, including population selection, testing frequency, and testing methods. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Dalian Xinghai Medical Forum, Oncology Frontier invited Professor Baoliang Guo from The Second Affiliated Hospital of Harbin Medical University, Professor Guiying Xu from Jilin Cancer Hospital to discuss the application of ctDNA monitoring in breast cancer.

Xinghai Forum: Professors Pengfei Qiu and Hao Wang Share Research Progress on ctDNA Monitoring in Breast Cancer

By Mourabit Halima 2024.07.09

Circulating tumor DNA (ctDNA) testing allows for continuous dynamic monitoring of tumor genetic variations without relying on tissue samples. This liquid biopsy technology has been widely used in clinical breast cancer research for prognosis and treatment evaluation, but there are still no standards for ctDNA testing, including population selection, testing frequency, and testing methods. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Dalian Xinghai Medical Forum, Oncology Frontier invited Professor Pengfei Qiu from Shandong Cancer Hospital, and Professor Hao Wang fro

the CHANGEABLE Phase II Study: Niraparib + HX008 for Safe and Effective Treatment of Germline BRCA1/2 Mutated MBC Patients

By Mourabit Halima 2024.07.09

In recent years, the rapid development of immunotherapy and targeted therapy has continuously updated the treatment strategies for metastatic breast cancer (MBC) patients. PARP inhibitors and immune checkpoint inhibitors, developed based on the concept of synthetic lethality, have become important treatment options for HER2- MBC patients, yet there remains a significant unmet need for treatment. Recently, at the ASCO 2024 conference, a collaborative team led by Professors Zhen Hu , Jian Zhang, and Yun Liu from Fudan University Shanghai Cancer Center shared the results of the Phase II CHANGEABLE study. This study revealed new hope for the combination of the PARP inhibitor niraparib and the PD-1 monoclonal antibody HX008 in MBC patients with germline DDR gene mutations. At ASCO 2024, Oncology Frontier interviewed Professor Jian Zhang to discuss the background, results, and significance of this study. The key insights are summarized below:

EHA International Perspective | Professor John Gribben Awarded the José Carreras Prize, Shares Key Factors Advancing Hematology

By Mourabit Halima 2024.07.09

At the recently held 29th Annual Congress of the European Hematology Association (EHA), Professor John Gribben, former chairman of EHA and head of the Hematological Center at Barts Cancer Institute, Queen Mary University of London, was awarded the José Carreras Prize for his outstanding contributions in the field of immunology research. "Oncology Frontier-Hematology Frontier" specially invited Professor John Gribben to share his research findings and his feelings about the award. In addition, Professor John Gribben also discussed the significance of patient-centered treatment in the field of hematology and emphasized the importance of global cooperation and inclusive clinical trials to advance the field and provide the best care for patients worldwide.

EHA International Perspective | Professor Jean-Pierre Bourquin: Advances in Drug Resistance Research for Acute Lymphoblastic Leukemia (ALL)

By Mourabit Halima 2024.07.08

Acute Lymphoblastic Leukemia (ALL), as an aggressive form of blood cancer, poses a serious threat to patients' lives. Despite significant progress in treatment in recent years, drug resistance remains a major obstacle to improving patient survival rates and quality of life. At the recently held 29th Annual Congress of the European Hematology Association (EHA 2024), the research findings of Professor Jean-Pierre Bourquin from the Universitätsspital Zürich, Zürich, Switzerland , were particularly significant. The research has not only made important contributions to understanding the complex biological mechanisms of ALL but also achieved breakthrough progress in the study of drug resistance. "Oncology Frontier - Hematology Frontier" specially invited Professor Bourquin to share the core theme of precision hematology and his key findings in the research of ALL drug resistance at the venue.

EHA 2024 | Conference Chairman Professor Antonio Almeida: Join Hands to Create the Future of Hematology Together

By El Bachir MOURABIT 2024.07.08

The 29th Annual Congress of the European Hematology Association (EHA) was held in Madrid, Spain, from June 13 to 16, 2024. This conference is the largest international event in the field of European hematology, attracting numerous internationally renowned experts and scholars every year to share and discuss innovative ideas, the latest scientific research, and clinical research results in the field of hematology. At this conference, "Oncology Frontier - Hematology Frontier" specially invited Professor Antonio Almeida, the Chairman of the EHA Conference and the founding dean of the Hospital da Luz and Católica Medical School in Lisbon, Portugal, Lisbon, Portugal, to discuss the main highlights and important progress of the conference, covering a range of topics including breakthrough research, international cooperation, and the future challenges in the field of hematology.